Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes

BMC Cardiovascular Disorders

Volumn 15, Issue 1, 2015, Pages

  Niu, Yixin ^a   Zhang, Weiwei ^a   Yang, Zhen ^a   Li, Xiaoyong ^a   Wen, Jie ^b   Wang, Suijun ^c   Zhang, Hongmei ^a   Wang, Xuanchun ^b   Zhou, Houguang ^b   Fang, Wenjun ^a   Qin, Li ^a   Su, Qing ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL; URIC ACID; ADIPOQ PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEG ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; BLOOD; COHORT ANALYSIS; COLOR DOPPLER FLOWMETRY; COMPLICATION; DIAGNOSTIC IMAGING; LOWER LIMB; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULARIZATION;

ADIPONECTIN; ADULT; AGED; C-REACTIVE PROTEIN; COHORT STUDIES; CONSTRICTION, PATHOLOGIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 84938801047     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-015-0079-0     Document Type: Article

References (28)

1. Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res. 2005;37:90-4.
2. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-4.
3. Kim J, Song TJ, Yang SH, Lee OH, Nam HS, Kim YD, et al. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis. Clin Biochem. 2013;46:1036-40.
4. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney Jr JF, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol. 2010;30:1849-54.
5. Stepien E, Wypasek E, Stopyra K, Konieczyńska M, Przybyło M, Pasowicz M. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin)in hypertensive individuals. Clin Biochem. 2011;44:826-31.
6. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-8.
7. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol. 2005;63:594-8.
8. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-8.
9. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011;10:76.
10. O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010;126:e423-427.
11. Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012;46:203-11.
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. (1997). Diabetes Care, 20, 1183-1197.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
14. Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ. Guidelines for noninvasive vascular laboratory testing: A report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006;19:955-72.
15. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin /RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801-11.
16. Ali Z, Ellington AA, Mosley Jr TH, Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis. 2009;206:575-80.
17. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. J Thromb Haemost. 2010;8:2133-9.
18. Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M, Bjerre M, Forsblom C, Flyvbjerg A, Groop PH, FinnDiane Study Group. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care. 2013;36:1827-33.
19. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549-53.
20. Zhou S, Fang X, Xin H, Li W, Qiu H, Guan S. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway. PLoS ONE. 2013;8, e68987.
21. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors rankl and osteoprotegerin. Circ Res. 2004;95:1046-57.
22. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:1924-8.
23. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004;74:103-6.
24. Rogers A, Eastell R. REVIEW: Circulating osteoprotegerin and receptor activator for nuclear factor-κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90:6323-31.
25. Kadoglou NP, Papadakis I, Moulakakis KG, Ikonomidis I, Alepaki M, Moustardas P, et al. Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. Regul Pept. 2012;179:50-4.
26. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerinis a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-80.
27. Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol. 2006;64:652-8.
28. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum in men: correlation with age, Estrogen, and testosterone status. J Clin Endocrinol Metab. 2001;86:3162-5.